Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Final O'Neill Review Suggests Supra-National AMR Body & Pharma Levy

Executive Summary

Antimicrobial Resistance (AMR) is a huge economic and security threat necessitating immediate coordinated action and pooled funding by a global coalition of governments, institutions, companies and NGOs, Jim O'Neill says in his review's final report on the topic, which outlines a menu of options for accomplishing that – including a levy on the pharma sector – and says a supra-national entity will also be needed to tackle AMR.

You may also be interested in...



Wellcome Trust Makes AMR Strategic Priority After Funding O'Neill Review

Britain's well-endowed and influential Wellcome Trust which co-funded the O'Neill Review on how to tackle antimicrobial resistance has now made AMR one of its strategic priorities and aims to raise its profile with it. Wellcome policy head Ed Whiting outlines next steps in an interview with the Pink Sheet.

Jim O’Neill Is “Free For Global AMR Role” After Leaving UK Government

Having suddenly resigned from the UK government, Jim O’Neill says he’s now available to take on a global role, if asked, to promote concrete action on tackling antimicrobial resistance within promised timeframes.

Jim O’Neill Is “Free For Global AMR Role” After Leaving UK Government

Having suddenly resigned from the UK Government Jim O’Neill says he’s now available to take on a global role, if asked, to promote concrete action on tackling antimicrobial resistance within promised timeframes.

Topics

UsernamePublicRestriction

Register

SC065224

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel